Details for Patent: 9,850,229
✉ Email this page to a colleague
Which drugs does patent 9,850,229 protect, and when does it expire?
Patent 9,850,229 protects BRAFTOVI and MEKTOVI and is included in two NDAs.
This patent has seventy-five patent family members in forty-nine countries.
Summary for Patent: 9,850,229
| Title: | Compounds and compositions as protein kinase inhibitors |
| Abstract: | The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf. |
| Inventor(s): | Huang; Shenlin (San Diego, CA), Jin; Xianming (San Ramon, CA), Liu; Zuosheng (San Diego, CA), Poon; Daniel (Piedmont, CA), Tellew; John (La Jolla, CA), Wan; Yongqin (Irvine, CA), Wang; Xing (San Diego, CA), Xie; Yongping (San Diego, CA) |
| Assignee: | Array BioPharma, Inc. (Boulder, CO) |
| Application Number: | 15/179,385 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,850,229 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Dosage form; |
Drugs Protected by US Patent 9,850,229
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Array Biopharma Inc | BRAFTOVI | encorafenib | CAPSULE;ORAL | 210496-001 | Jun 27, 2018 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | INDICATED IN COMBINATION WITH BINIMETINIB FOR THE TREATMENT OF MELANOMA WITH A BRAF MUTATION | ⤷ Sign Up | ||||
| Array Biopharma Inc | BRAFTOVI | encorafenib | CAPSULE;ORAL | 210496-002 | Jun 27, 2018 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | INDICATED IN COMBINATION WITH BINIMETINIB FOR THE TREATMENT OF MELANOMA WITH A BRAF MUTATION | ⤷ Sign Up | ||||
| Array Biopharma Inc | MEKTOVI | binimetinib | TABLET;ORAL | 210498-001 | Jun 27, 2018 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | INDICATED IN COMBINATION WITH ENCORAFENIB FOR THE TREATMENT OF MELANOMA WITH A BRAF MUTATION | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,850,229
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2470526 | ⤷ Sign Up | PA2019005 | Lithuania | ⤷ Sign Up |
| European Patent Office | 2727918 | ⤷ Sign Up | PA2019006 | Lithuania | ⤷ Sign Up |
| European Patent Office | 2470526 | ⤷ Sign Up | 300973 | Netherlands | ⤷ Sign Up |
| European Patent Office | 2727918 | ⤷ Sign Up | 300975 | Netherlands | ⤷ Sign Up |
| European Patent Office | 2470526 | ⤷ Sign Up | LUC00101 | Luxembourg | ⤷ Sign Up |
| European Patent Office | 2470526 | ⤷ Sign Up | 122019000021 | Germany | ⤷ Sign Up |
| European Patent Office | 2470526 | ⤷ Sign Up | 2019C/508 | Belgium | ⤷ Sign Up |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
